CTLA4 and leukemia: We saw a moderate but solid reduction in stem cell-like cells with the checkpoint inhibitors CTLA4 or PD-1 alone, and again we saw that the combination of these immunotherapeutics did not enhance these anti-leukemia effects [14, 27].